Eric Wu

Also affiliated with University of Pittsburgh Medical Center, ORCID

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease”.

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Blood Advances(2024)10.1182/bloodadvances.2023012467

N/A

0.766DataRank · unranked

29 citations

Robert Hagar, Modupe Idowu, Ifeyinwa Osunkwo, Kimberly Cruz, Frans A. Kuypers +10 more

Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

Blood(2024)10.1182/blood-2024-204962

N/A

0DataRank · unranked

7 citations

Fuad El Rassi, Biree Andemariam, Miguel R. Abboud, Julie Kanter, Marilyn J. Telen +7 more